PFE · Pfizer Inc

$28.26 +1.01 (+3.69%)

Market Cap

$155.52B

5.70B

Named-executive compensation from the company's DEF 14A proxy statements — salary, bonus, stock and option awards, non-equity incentive, and the company-reported total per executive per fiscal year, exactly as disclosed in the Summary Compensation Table.

Fiscal 2025

Executive	Role	Salary	Bonus	Stock Awards	Option Awards	Incentive	Other	Total
A. Bourla	Chairman and Chief Executive Officer	$1,800,000	—	$9,442,705	$8,998,141	$5,400,000	$1,940,441	$27,585,301
C. Boshoff	Chief Scientific Officer and President, Research & Development	$1,400,000	—	$1,808,655	$2,999,378	$3,150,000	$648,006	$10,006,039
D. Denton	Chief Financial Officer, EVP	$1,388,964	—	$2,367,893	$2,499,485	$2,800,000	$613,840	$9,670,182
A. Malik	Chief U.S. Commercial Officer, EVP	$1,386,817	—	$2,281,630	$2,249,535	$2,900,000	$611,245	$9,429,227
D. Lankler	Chief Legal Officer, EVP	$1,411,787	—	$1,976,390	$2,249,535	$2,675,000	$535,588	$9,106,276

Fiscal 2024

Executive	Role	Salary	Bonus	Stock Awards	Option Awards	Incentive	Other	Total
A. Bourla	Chairman and Chief Executive Officer	$1,800,000	—	$4,838,694	$9,993,969	$7,020,000	$996,064	$24,648,727
M. Dolsten	Chief Scientific Officer, President, Pfizer Research & Development	$1,654,300	—	$1,565,751	$3,318,434	$2,895,200	$309,604	$9,743,289
A. Malik	Chief U.S. Commercial Officer, EVP	$1,344,825	—	$1,127,148	$2,475,933	$3,093,200	$253,164	$8,294,270
D. Denton	Chief Financial Officer, EVP	$1,346,925	—	$1,130,214	$2,447,055	$2,963,400	$236,948	$8,124,542
C. Boshoff	Chief Scientific Officer and President, Research & Development	$1,200,000	—	$896,297	$2,249,857	$2,880,000	$627,830	$7,853,984
D. Lankler	Chief Legal Officer, EVP	$1,244,588	—	$913,346	$1,935,758	$2,464,400	$244,779	$6,814,115

Fiscal 2023

Executive	Role	Salary	Bonus	Stock Awards	Option Awards	Incentive	Other	Total
A. Bourla	Chairman and Chief Executive Officer	$1,787,500	—	$8,745,187	$8,761,683	$0	$2,259,254	$21,562,064
M. Dolsten	Chief Scientific Officer, President, Pfizer Research & Development	$1,596,500	—	$3,115,268	$2,920,565	$0	$812,397	$8,858,700
A. Hwang	Former Chief Commercial Officer and President, Global Biopharmaceuticals Business	$1,340,450	—	$2,336,483	$2,190,418	$0	$679,897	$6,693,779
W. Pao	Former Chief Development Officer, EVP	$772,500	$691,939	$577,860	$1,703,661	—	$2,505,158	$6,251,118
D. Lankler	General Counsel, EVP	$1,198,313	—	$1,817,208	$1,703,661	$0	$561,892	$5,477,798
A. Malik	Chief U.S. Commercial Officer, EVP	$1,294,800	—	$1,336,257	$2,190,418	$0	$599,259	$5,420,734
D. Denton	Chief Financial Officer, EVP	$1,296,875	—	$1,341,079	$2,190,418	$0	$451,164	$5,279,536

Fiscal 2022

Executive	Role	Salary	Bonus	Stock Awards	Option Awards	Incentive	Other	Total
A. Bourla	Chairman and Chief Executive Officer	$1,737,500	—	$9,296,191	$9,526,444	$7,650,000	$2,333,571	$33,017,453
D. Denton	Chief Financial Officer, EVP	$833,333	$5,000,000	$4,000,012	$2,250,008	$1,838,355	$10,522,450	$24,444,158
W. Pao	Former Chief Development Officer, EVP	$937,500	$5,000,000	$5,999,988	—	$1,565,557	$3,760,971	$17,264,016
M. Dolsten	Chief Scientific Officer, President, Pfizer Research & Development	$1,535,000	—	$3,471,267	$2,931,212	$3,530,972	$749,782	$12,218,233
F. D’Amelio	Former Chief Financial Officer, EVP	$1,448,333	—	$3,703,779	$2,931,212	$1,445,808	$1,009,534	$10,538,666
A. Hwang	Former Chief Commercial Officer and President, Global Biopharmaceuticals Business	$1,276,500	—	$2,661,590	$2,198,403	$2,936,438	$673,437	$9,746,368
D. Lankler	General Counsel, EVP	$1,143,750	—	$2,160,626	$1,709,885	$2,264,931	$547,163	$7,826,355

Fiscal 2021

Executive	Role	Salary	Bonus	Stock Awards	Option Awards	Incentive	Other	Total
A. Bourla	Chairman and Chief Executive Officer	$1,687,500	—	$6,180,808	$7,050,649	$8,000,000	$1,384,361	$24,353,219
F. D’Amelio	Former Chief Financial Officer, EVP	$1,571,250	—	$2,840,271	$3,021,712	$2,925,000	$647,000	$11,037,327
M. Dolsten	Chief Scientific Officer, President, Pfizer Research & Development	$1,478,750	—	$2,531,393	$3,021,712	$3,250,000	$633,135	$10,914,990
A. Hwang	Former Chief Commercial Officer and President, Global Biopharmaceuticals Business	$1,220,000	—	$1,975,798	$2,266,282	$2,984,700	$586,154	$9,032,934
J. Young	Former Group President, Chief Business Officer	$1,322,750	—	$1,893,548	$2,014,472	$2,387,800	$477,015	$8,332,681
D. Lankler	General Counsel, EVP	$1,102,500	—	$1,587,984	$1,762,662	$2,191,860	$484,366	$7,129,372

Fiscal 2020

Executive	Role	Salary	Bonus	Stock Awards	Option Awards	Incentive	Other	Total
A. Bourla	Chairman and Chief Executive Officer	$1,650,000	—	$4,897,817	$6,782,951	$5,491,800	$843,222	$21,033,570
F. D’Amelio	Former Chief Financial Officer, EVP	$1,533,750	—	$2,406,437	$3,130,596	$2,470,000	$517,016	$11,376,096
M. Dolsten	Chief Scientific Officer and President, Worldwide Research, Development and Medical	$1,433,750	—	$2,110,585	$2,608,832	$2,600,000	$467,819	$10,149,624
J. Young	Former Group President, Chief Business Officer	$1,285,000	—	$1,814,734	$2,087,062	$1,800,000	$450,994	$8,989,193
A. Hwang	Chief Commercial Officer and President, Global Biopharmaceuticals Business	$1,142,500	—	$1,420,129	$2,087,062	$2,387,800	$440,714	$7,883,447

Fiscal 2019

Executive	Role	Salary	Bonus	Stock Awards	Option Awards	Incentive	Other	Total
A. Bourla	Chairman and Chief Executive Officer	$1,600,000	—	$4,290,956	$6,075,290	$3,630,000	$606,269	$17,928,963
I. Read	Executive Chairman	$1,200,000	—	$6,743,656	$4,050,197	$2,520,000	$788,355	$16,286,465
F. D’Amelio	Chief Financial Officer, EVP, Global Supply	$1,500,000	—	$2,582,446	$3,037,649	$1,820,000	$523,472	$11,075,730
M. Dolsten	Chief Scientific Officer, President, Worldwide Research, Development and Medical	$1,400,000	—	$2,414,725	$2,531,376	$1,820,000	$444,701	$9,598,045
J. Young	Former Group President, Chief Business Officer	$1,245,000	—	$2,247,004	$2,025,093	$1,675,000	$441,439	$8,959,383

Fiscal 2018

Executive	Role	Salary	Bonus	Stock Awards	Option Awards	Incentive	Other	Total
I. Read	Executive Chairman	$1,992,500	—	$7,030,630	$6,854,237	$3,000,000	$671,846	$19,549,213
A. Bourla	Chairman and Chief Executive Officer	$1,400,000	—	$2,592,079	$3,954,369	$1,533,000	$375,109	$9,854,557
F. D’Amelio	Chief Financial Officer and EVP, Global Supply	$1,407,917	—	$2,013,091	$2,108,995	$1,310,000	$299,826	$7,139,829
J. Young	Chief Business Officer, Group President	$1,206,250	—	$2,013,091	$2,108,995	$1,385,000	$408,379	$7,121,715
M. Dolsten	Chief Scientific Officer, President, Worldwide Research, Development and Medical	$1,306,250	—	$2,013,091	$2,108,995	$1,326,000	$315,863	$7,070,199

Fiscal 2017

Executive	Role	Salary	Bonus	Stock Awards	Option Awards	Incentive	Other	Total
I. Read	Executive Chairman	$1,956,750	—	$6,631,652	$14,504,377	$2,600,000	$472,359	$27,913,775
J. Young	Chief Business Officer, Group President	$1,170,000	—	$3,882,186	$3,801,214	$1,015,000	$481,210	$11,506,110
A. Bourla	Chief Executive Officer	$1,170,000	—	$1,651,093	$1,801,215	$1,260,000	$186,324	$8,836,301
F. D’Amelio	Chief Financial Officer, EVP, Business Operations and Global Supply	$1,356,750	—	$1,882,190	$1,801,215	$1,120,000	$190,740	$8,298,034
M. Dolsten	Chief Scientific Officer, President, Worldwide Research, Development and Medical	$1,271,250	—	$1,882,190	$1,801,215	$1,150,000	$233,351	$7,670,815

Executive changes

Person	Role	Change	Effective	Filed
Cecile Guegan	Interim Chief Financial Officer	Appointed	2026-08-16	2026-06-18
Angela Hwang	Chief Commercial Officer, Executive Vice President	Terminated	2023-12-15	2023-12-12
Alexandre de Germay	Chief International Commercial Officer, Executive Vice President	Appointed	2023-12-15	2023-12-12
Aamir Malik	Chief U.S. Commercial Officer, Executive Vice President	Appointed	2023-12-15	2023-12-12
Dr. Chris Boshoff	Chief Oncology Officer, Executive Vice President	Appointed	2023-12-15	2023-12-12
Dr. William Pao	Chief Development Officer, Executive Vice President	Terminated	2023-08-15	2023-07-27
Dr. Chris Boshoff	Chief Oncology Research and Development Officer, Executive Vice President	Appointed	—	2023-07-27
David M. Denton	Chief Financial Officer, Executive Vice President	Appointed	2022-05-02	2022-04-12
Mike McDermott	Executive Vice President, Chief Global Supply Officer	Appointed	2022-01-01	2021-11-19
Frank D'Amelio	Chief Financial Officer and Executive Vice President of Global Supply	Retired	—	2021-11-19

Key facts CIK 78003 CUSIP 717081103 13F (30d) 2432 filings 2340 filers Visit website Investor relations